Haemophilia

Article	Citations
Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A	73
Emicizumab prophylaxis: Prospective longitudinal real‐world follow‐up and monitoring	42
Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real‐world experience from a large comprehensive treatment centre in the US	42
European principles of care for women and girls with inherited bleeding disorders	40
Genetic causes of haemophilia in women and girls	39
Delivery of AAV‐based gene therapy through haemophilia centres—A need for re‐evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC	37
Low immunogenicity of emicizumab in persons with haemophilia A	34
Emicizumab state‐of‐the‐art update	33
Evidence of a disability paradox in patient‐reported outcomes in haemophilia	31
Off‐label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: A scoping review of the literature	30
Outcome measures in Haemophilia: Beyond ABR (Annualized Bleeding Rate)	29
Long‐term safety and efficacy of emicizumab for up to 5.8 years and patients’ perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A	28
Patient perspectives regarding gene therapy in haemophilia: Interviews from the PAVING study	27
Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real‐world data	27
The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies	25
Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays	24
Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery	23
Emicizumab prophylaxis in infants with severe haemophilia A without inhibitors: Illustrative real‐world cases to support shared decision‐making	21
The Function of extravascular coagulation factor IX in haemostasis	21
Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update	21
Health‐related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors—A non‐interventional study	20
Clinical phenotype of severe and moderate haemophilia: Who should receive prophylaxis and what is the target trough level?	20
Comparison of bypassing agents in patients on emicizumab using global hemostasis assays	20
An overview of patients with haemophilia A in China: Epidemiology, disease severity and treatment strategies	20
An exploration of why men with severe haemophilia might not want gene therapy: The exigency study	20

How we diagnose 2M von Willebrand disease (VWD): Use of a strategic algorithmic approach to distinguish 2M VWD from other VWD types	20
Women and girls with haemophilia and bleeding tendencies: Outcomes related to menstruation, pregnancy, surgery and other bleeding episodes from a retrospective chart review	19
Women and girls with haemophilia receiving care at specialized haemophilia treatment centres in the United States	19
Therapeutic and technological advancements in haemophilia care: Quantum leaps forward	18
Health issues in women and girls affected by haemophilia with a focus on nomenclature, heavy menstrual bleeding, and musculoskeletal issues	18
Patient preferences and priorities for haemophilia gene therapy in the US: A discrete choice experiment	18
Gene therapy: Practical aspects of implementation	17
Lower physical activity and altered body composition in patients with haemophilia compared with healthy controls	17
The 2021 von Willebrand disease guidelines: Clarity and controversy	16
Practical considerations for nonfactor‐replacement therapies in the treatment of haemophilia with inhibitors	16
Effectiveness of monthly low dose emicizumab prophylaxis without 4‐week loading doses among patients with haemophilia A with and without inhibitors: A case series report	16
Pathological coagulation parameters in as many as 54 patients with autoimmune acquired factor XIII deficiency due to anti–factor XIII autoantibodies	16
Detection and evaluation of haemophilic arthropathy: Which tools may be considered more reliable	16
Evolution of haemophilia integrated care in the era of gene therapy: Treatment centre’s readiness in United States and EU	15
Real‐world cost estimates of initiating emicizumab in US patients with haemophilia A	15
Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study	15
Comparative analysis of the pivotal studies of extended half‐life recombinant FVIII products for treatment of haemophilia A	15
Parental perspectives on gene therapy for children with haemophilia: The Exigency study	15
The relationship between chronic pain and psychosocial aspects in patients with haemophilic arthropathy. A cross‐sectional study	15
Management of COVID‐19‐associated coagulopathy in persons with haemophilia	14
Occurrence rates of von Willebrand disease among people receiving care in specialized treatment centres in the United States	14
POSTER ABSTRACTS	14
Low dose emicizumab prophylaxis in haemophilia a patients: A pilot study from India	14
Managing women‐specific bleeding in inherited bleeding disorders: A multidisciplinary approach	14
Impact of haemophilia on patients with mild‐to‐moderate disease: Results from the P‐FiQ and B‐HERO‐S studies	14
Efficacy of emicizumab in von Willebrand disease (VWD) patients with and without alloantibodies to von Willebrand factor (VWF): Report of two cases and review of literature	14
Gaining more insight into ankle pain in haemophilia: A study exploring pain, structural and functional evaluation of the ankle joint	14
Efficacy and safety of fibrinogen concentrate for on‐demand treatment of bleeding and surgical prophylaxis in paediatric patients with congenital fibrinogen deficiency	14
Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study	14
Clinical assessment and point of care ultrasonography: How to diagnose haemophilic synovitis	14
Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with hae	13
A systematic review of physical activity in people with haemophilia and its relationship with bleeding phenotype and treatment regimen	13
Diagnosis of von Willebrand disease: An assessment of the quality of testing in North American laboratories	13
Similar sports participation as the general population in Dutch persons with haemophilia; results from a nationwide study	13
Befovacimab, an anti‐tissue factor pathway inhibitor antibody: Early termination of the multiple‐dose, dose‐escalating Phase 2 study due to thrombosis	13
Adoption of emicizumab (Hemlibra®) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey	13
Effectiveness of emicizumab in preventing life‐threatening bleeding complications in type 3 von Willebrand disease with inhibitors: A paediatric report	13
Prophylaxis in children with haemophilia in an evolving treatment landscape	13
Gynaecological management of women with inherited bleeding disorders. A UK Haemophilia Centres Doctors' Organisation Guideline	13
Patient preferences for gene therapy in haemophilia: Results from the PAVING threshold technique survey	13
Natural anticoagulants: A missing link in mild to moderate bleeding tendencies	13
A case of acquired haemophilia A in a 70‐year‐old post COVID‐19 vaccine	13
Acquired haemophilia A in the postpartum and risk of relapse in subsequent pregnancies: A systematic literature review	13
Patients’ and parents’ satisfaction with, and preference for, haemophilia A treatments: a cross‐sectional, multicentre, observational study	12
Gene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and EHC	12
Cost‐effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti‐FVIII inhibitors in France	12
Alternative payment models for durable and potentially curative therapies: The case of gene therapy for haemophilia A	12
Emicizumab improves thrombus formation of type 2A von willebrand disease under high shear condition	12
Real‐world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors	12
The B‐Natural study—The outcome of immune tolerance induction therapy in patients with severe haemophilia B	12

Activity and participation in haemophiliacs: Item response modelling based on international classification of functioning, disability and health	12
Assessing the test–retest reliability and smallest detectable change of the Haemophilia Activities List	12
Feasibility and outcomes of low‐dose and low‐frequency prophylaxis with recombinant extended half‐life products (Fc‐rFVIII and Fc‐rFIX) in Ivorian children with hemophilia: Two‐year experience in the	12
Individualised prophylaxis based on personalised target trough FVIII level optimised clinical outcomes in paediatric patients with severe haemophilia A	11
All‐cause mortality and causes of death in persons with haemophilia: A systematic review and meta‐analysis	11
Predictors of inhibitor eradication by primary immune tolerance induction in severe haemophilia A with high responding inhibitors	11
Immune tolerance induction in the era of emicizumab – still the first choice for patients with haemophilia A and inhibitors?	11
Do we need all that emicizumab?	11
Vaccination against COVID‐19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders	11
Clinical attributes and treatment characteristics are associated with work productivity and activity impairment in people with severe haemophilia A	11
Identified unmet needs and proposed solutions in mild‐to‐moderate haemophilia: A summary of opinions from a roundtable of haemophilia experts	11
Osteoporosis management and falls prevention in patients with haemophilia: Review of haemophilia guidelines	11
Validation of a new instrument to measure disease‐related distress among patients with haemophilia	11
Synovitis and joint health in patients with haemophilia: Statements from a European e‐Delphi consensus study	11
Promoting physical activity for people with haemophilia in the age of new treatments	10
POSTER PRESENTATIONS	10
Pain, depression and anxiety in people with haemophilia from three Nordic countries: Cross‐sectional survey data from the MIND study	10
Management and outcomes of paediatric patients on emicizumab prophylaxis undergoing surgical procedures: Experience from a large haemophilia centre in the UK	10
Effects of a non‐pharmacological approach for chronic pain management in patients with haemophilia: efficacy of cognitive‐behavioural therapy associated with physiotherapy	10
Managing invasive procedures in haemophilia patients with limited resources, extended half‐life concentrates or non‐replacement therapies in 2022	10
Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies	10
Big picture initiatives in bleeding disorders	10
Most subjectively affected joints in patients with haemophilia – what has changed after 20 years in Germany?	10
Factor product utilization and health outcomes in patients with haemophilia A and B on extended half‐life concentrates: A Canadian observational study of real‐world outcomes	10
Exercise capacity in people with haemophilia: A systematic review	10
Building the blueprint: Formulating a community‐generated national plan for future research in inherited bleeding disorders	10
Health technology assessment for gene therapies in haemophilia	10
Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) study	10
Global epidemiology of factor XI deficiency: A targeted review of the literature and foundation reports	10
PROTECT VIII kids extension study: Long‐term safety and efficacy of BAY 94‐9027 (damoctocog alfa pegol) in children with severe haemophilia A	10
Validation of the pictorial blood loss assessment chart using modern sanitary products	10
Drug‐associated acquired hemophilia A: an analysis based on 185 cases from the WHO pharmacovigilance database	10
A preliminary application of a haemophilia value framework to emerging therapies in haemophilia	10
Abstract	10
Quantitative measurements of haemophilic joint tissues by point‐of‐care musculoskeletal ultrasound: Associations with clinical and functional joint outcome parameters	10
Real‐world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure:	9
An evaluation of PROMIS health domains in adults with haemophilia: A cross‐sectional study	9
Towards achieving a haemophilia‐free mind	9
Haemophilia gene therapy—Update on new country initiatives	9
Descriptive analysis of bleeding symptoms in haemophilia carriers enrolled in the ATHNdataset	9
Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B	9
Real‐world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow‐up in a national adult cohort	9
Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study	9
Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A	9
Ultrasound evaluation of joint damage and disease activity in adult patients with severe haemophilia A using the HEAD‐US system	9
Pharmacokinetic‐guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A	9
Addressing patient education priorities in the era of gene therapy for haemophilia: Towards evidence‐informed shared decision‐making	9
Acquired bleeding disorders	9
Efficacy and safety of a recombinant Von Willebrand Factor treatment in patients with inherited Von Willebrand Disease requiring surgical procedures	9
Low rate of subclinical venous thrombosis in patients with haemophilia undergoing major orthopaedic surgery in the absence of pharmacological thromboprophylaxis	9
Targeting higher factor VIII levels for prophylaxis in haemophilia A: a narrative review	9
Bone health in haemophilia carriers and persons with von Willebrand disease: A large database analysis	9
Occurrence and management of severe bleeding episodes in patients with hereditary factor X deficiency	8
Long‐term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post‐treatment	8
Assessment of the clinical perception, quality of life and satisfaction of patients with severe congenital haemophilia A without inhibitor after 1 year of emicizumab therapy	8
Reimbursing the value of gene therapy care in an era of uncertainty	8
Effectiveness of physical exercise on postural balance in patients with haemophilia: A systematic review	8
Gene therapy preferences and informed decision‐making: Results from a National Hemophilia Foundation Community Voices in research survey	8
Emicizumab for the treatment of acquired hemophilia A: Retrospective review of a single‐institution experience	8
The GOAL‐Hēm journey: Shared decision making and patient‐centred outcomes	8
Towards novel treatment options in von Willebrand disease	8
Switching from standard to extended half‐life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics	8
rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B: Post hoc analysis of B‐LONG using haemophilia‐specific quality of life questionnaires	8
Long‐term joint outcomes in adolescents with moderate or severe haemophilia A	8
Clinical and patient reported outcome in total ankle replacement compared to ankle fusion in end‐stage haemophilic arthropathy	8
Laboratory coagulation tests and recombinant porcine factor VIII: A United Kingdom Haemophilia Centre Doctors’ Organisation guideline	8
Depression and anxiety in persons with Von Willebrand disease	8
COVID‐19 and telemedicine in haemophilia in a patient with severe haemophilia A and orthopaedic surgery	8
Bleeding with iron deposition and vascular remodelling in subchondral cysts: A newly discovered feature unique to haemophilic arthropathy	8
Recurrence of a high‐titre factor VIII inhibitor in a haemophilia A patient on emicizumab prophylaxis	8
Humanistic burden of problem joints for children and adults with haemophilia	8
Pharmacokinetic, efficacy and safety evaluation of B‐domain‐deleted recombinant FVIII (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A	8
Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A – A modified Delphi consensus by the ADVANCE Working Gro	8
Adherence to prophylaxis and its association with activation of self‐management and treatment satisfaction	8
The evolution of physiotherapy in the multidisciplinary management of persons with haemophilia (PWH): A scoping review	8
Examining patient and professional perspectives in the UK for gene therapy in haemophilia	8
The effects of manual therapy on musculoskeletal system, functional level, joint health and kinesiophobia in young adults with severe haemophilia: A randomized pilot study	8
Challenges of antithrombotic therapy in the management of cardiovascular disease in patients with inherited bleeding disorders: A single‐centre experience	8
How to assess, detect, and manage joint involvement in the era of transformational therapies: Role of point‐of‐care ultrasound	8
A comparison of MyPKFiT and WAPPS‐Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa	8

Safety of FEIBA and emicizumab (SAFE): Dose escalation study evaluating the safety of in vivo administration of activated prothrombin complex concentrate in haemophilia A patients on emicizumab	7
The views of women with bleeding disorders: Results from the Cinderella study	7
Approximation of emicizumab plasma levels in emergency situations. A practical approach	7
Association of factor expression levels with annual bleeding rate in people with haemophilia B	7
European principles of care for physiotherapy provision for persons with inherited bleeding disorders: Perspectives of physiotherapists and patients	7
Emicizumab enhances thrombus formation in vitro under high shear flow conditions in whole blood from patients with type 1 and type 3 von Willebrand disease	7
Dilemmas on emicizumab in children with haemophilia A: A survey of strategies from PedNet centres	7
Advantages of external quality assessment‐EQA programs	7
Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma	7
Reappearance of inhibitor in a tolerized patient with severe haemophilia A during FVIII‐free emicizumab therapy	7
Haemophilia management and treatment: An Italian survey on patients’, caregivers’ and clinicians’ point of view	7
Emicizumab reduces re‐hospitalization for bleeding in acquired haemophilia A	7
Pain memories: A new concept to consider in the management of chronic pain in people with haemophilia	7
Single centre, real‐world experience of perioperative rFIXFc use in adult patients with haemophilia B undergoing major and minor surgery	7
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors	7
The role of total ankle replacement in patients with haemophilia and end‐stage ankle arthropathy: A review	7
Emicizumab prophylaxis in haemophilia A with inhibitors: Three years follow‐up from the UK Haemophilia Centre Doctors’ Organisation (UKHCDO)	7
Comparison of free‐living physical activity measurements between ActiGraph GT3X‐BT and Fitbit Charge 3 in young people with haemophilia	7
Ultrasound and patient self‐imaging in hemophilia	7
Low dose prophylaxis and antifibrinolytics: Options to consider with proven benefits for persons with haemophilia	7
Gene therapy – are we ready now?	7
Mutation analysis in the F8 gene in 485 families with haemophilia A and prenatal diagnosis in China	7
Patient‐reported outcomes in autosomal inherited bleeding disorders: A systematic literature review	7
Implications of haemophilia gene therapy for the changing role of the multidisciplinary team	7
Subclinical synovial proliferation in patients with severe haemophilia A: The value of ultrasound screening and biochemical markers	7
Emicizumab for acquired haemophilia A: A case series	7
Thromboelastometry detects enhancement of coagulation in blood by emicizumab via intrinsic pathway	7
Development of a haemophilia A gene therapy shared decision‐making tool for clinicians	7
A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one‐stage clotting and chromogenic substrate assays at clinical haemostasis laboratories	7
How mild is mild haemophilia?	7
How good does ChatGPT answer frequently asked questions about haemophilia?	7
Aerobic exercise in patients with haemophilia: A systematic review on safety, feasibility and health effects	7
Thrombomodulin in patients with mild to moderate bleeding tendency	7
Isokinetic knee strength deficit in patients with moderate haemophilia	7
von Willebrand disease and von Willebrand factor	6
Shortening the Haemophilia Activities List (HAL) from 42 items to 18 items	6
Demographics, clinical profile and treatment landscape of patients with haemophilia B in China	6
Bleeding events in people with congenital haemophilia A without factor VIII inhibitors receiving prophylactic factor VIII treatment: A systematic literature review	6
Acquired haemophilia A: A 15‐year population‐based review of incidence rate, patient demographics and treatment outcomes	6
Natural history study of factor IX deficiency with focus on treatment and complications (B‐Natural)	6
Developing clinical practice guidelines for physiotherapists working with people with inherited bleeding disorders	6
Reported prevalence of von Willebrand disease worldwide in relation to income classification	6
Biomarkers and immunological parameters in haemophilia and rheumatoid arthritis patients: a comparative multiplexing laboratory study	6
Treatment outcomes in persons with severe haemophilia B in the Nordic region: The B‐NORD study	6
A phase IV, multicentre, open‐label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures	6
The effects of manual therapy and exercises on pain, muscle strength, joint health, functionality and quality of life in haemophilic arthropathy of the elbow joint: A randomized controlled pilot study	6
Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors	6
Autoimmune acquired factor XIII deficiency in Japan 2021 update: Focused on annual incidence and clinical features	6
Bleeding patterns in patients before and after diagnosis of von Willebrand disease: Analysis of a US medical claims database	6
Preoperative bleeding risk assessment with ISTH‐BAT and laboratory tests in patients undergoing elective surgery: A prospective cohort study	6
Limited sampling strategies for accurate determination of extended half‐life factor VIII pharmacokinetics in severe haemophilia A patients	6
Ultrasound and magnetic resonance imaging for the detection of blood: An ex‐vivo study	6
Changes in pain profile of patients with haemophilia during 1‐year follow‐up	6
A qualitative study on the experiences of haemophilia carriers before, during and after pregnancy	6
Clinical characteristics and prognostic factors of acquired haemophilia A in Korea	6
Immune checkpoint inhibitor‐induced acquired haemophilia: A pharmacovigilance analysis of the FDA adverse event reporting system	6
ADAMTS‐4 as a possible distinguishing indicator between osteoarthritis and haemophilic arthropathy	6
Platelet function testing: Current practice among clinical centres in Northern Europe	6
IDEAL study: A real‐world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX‐FP) in patients with haemophilia B in Italy	6
Safety and efficacy of BAY 94–9027, an extended‐half‐life factor VIII, during minor surgical procedures in patients with severe haemophilia A	6
Prevalence and risk factors for hepatocellular carcinoma in individuals with haemophilia in the era of direct‐acting antiviral agents: A national inpatient sample study	6
Pain interferes with daily activities, emotions and sleep in adults with severe, moderate and mild haemophilia: A national cross‐sectional survey	6
Clinical, economic, and health‐related quality of life burden associated with von Willebrand disease in adults and children: Systematic and targeted literature reviews	6
Design, development and usability of an educational AI chatbot for People with Haemophilia in Senegal	6
FGF23 and SOX9 expression in haemophilic cartilage: In vitro studies of the effects of iron	6
Acquired von Willebrand syndrome and lymphoid neoplasms: A review of malignancy management, and propositions of practical recommendations	6
Real‐world evidence on health resource use among patients with haemophilia and inhibitor exhibiting severe bleeding episodes	6
Coordinating physiotherapy care for persons with haemophilia	6
Sports participation of patients with haemophilia in the COVID‐19 era: The Dutch experience	6
Safety of intramuscular COVID‐19 vaccination in patients with haemophilia	6
Outcomes of long‐term von Willebrand factor prophylaxis use in von Willebrand disease: A systematic literature review	6
A review of the pharmacokinetics, efficacy and safety of high‐purity factor X for the prophylactic treatment of hereditary factor X deficiency	5
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors	5
The humanistic and economic burden of problem joints for children and adults with moderate or severe haemophilia A: Analysis of the CHESS population studies	5
Prophylaxis use of clotting factor replacement products in people with non‐severe haemophilia: A review of the literature	5
Long‐term joint outcomes of regular low‐dose prophylaxis in Chinese children with severe haemophilia A	5
Expectation and loss when gene therapy for haemophilia is not an option: An exigency sub‐study	5
Physical activity, physical fitness and cardiometabolic risk amongst adults with moderate and severe haemophilia	5
Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders	5
Identification of non‐neutralizing anti‐factor X autoantibodies in three Japanese cases of autoimmune acquired factor X deficiency	5
Safety and efficacy of a self‐induced myofascial release protocol using a foam roller in patients with haemophilic knee arthropathy	5
Screening for subclinical synovial proliferation in haemophilia: A systematic review and meta‐analysis comparing physical examination and ultrasound	5
In vitro effects of emicizumab on activated clotting time in blood samples from cardiac surgical patients	5
Preparing for tomorrow: Defining a future agenda	5
Exercise variables and pain threshold reporting for strength training protocols in people with haemophilia: A systematic review of clinical trials	5
Port removal in patients receiving emicizumab prophylaxis: A single centre experience and review of the literature	5
Treatment of pelvic haemophilic pseudotumour: A retrospective study	5
Endothelial dysfunction and atherosclerosis related miRNA‐expression in patients with haemophilia	5
Results of a randomized phase III/IV trial comparing intermittent bolus versus continuous infusion of antihaemophilic factor (recombinant) in adults with severe or moderately severe haemophilia A unde	5
Dental habits and oral health in children and adolescents with bleeding disorders: A single‐institution cross‐sectional study	5
Real‐world prophylactic usage of recombinant factor VIII Fc in Sweden: A report from the Swedish national registry for bleeding disorders	5
Factor IX inhibitors in haemophilia B: A report of National Haemophilia Registry in China	5
Anti‐idiotype monoclonal antibodies against emicizumab enable accurate procoagulant and anticoagulant assays, irrespective of the test base, in the presence of emicizumab	5
Discordance between joint pain and imagery severity in the ankle joint and contributors of lower limb activity limitations in adults with haemophilia: A cross‐sectional study	5
Risk factors for increased perioperative blood loss during total knee arthroplasty in patients with haemophilia	5